EyePoint reports 2026 corporate update and key pivotal milestones for DURAVYU

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

EyePoint Pharmaceuticals provided a corporate update outlining its anticipated pivotal milestones for 2026 centered on the advancement of DURAVYU™ (vorolanib intravitreal insert), an investigational sustained-release therapy being developed for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company said its Phase 3 LUGANO and LUCIA trials in wet AMD have completed enrollment of more than 900 patients, marking rapid recruitment across both programs. Topline data from these pivotal trials are expected beginning in mid-2026, potentially informing a New Drug Application (NDA) submission and regulatory review plans.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE